Diseases /
Gastrointestinal Stromal Tumor
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor). It is a tumor that differentiates along the lines of interstitial cells of Cajal. Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor. However, many patients still experience recurrence. Conventional chemotherapy and radiation therapy have been of limited value. A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for gastrointestinal stromal tumor, 2 are FDA-approved in at least one setting and 3 have NCCN guidelines in at least one setting [3].
Avapritinib +
Disease is predicted to be sensitive: -
Dasatinib +
Imatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Imatinib is indicated for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: |
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Confers intermediate sensitivity; Higher doses of imatinib may be more effective. |
Disease is predicted to be resistant: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
Clinical Trials
There are 54 clinical trials for gastrointestinal stromal tumor, of which 42 are open and 12 are completed or closed. Of the trials that contain gastrointestinal stromal tumor as an inclusion criterion, 13 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), 24 are phase 2 (18 open), and 8 are phase 3 (6 open).
KIT, PDGFRA, and ANO1 are the most frequent gene inclusion criteria for gastrointestinal stromal tumor clinical trials [3].
Imatinib, regorafenib, and pembrolizumab are the most common interventions in gastrointestinal stromal tumor clinical trials.
Significant Genes in Gastrointestinal Stromal Tumor
ABL1 +
ABL1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ARID1A +
ARID1A is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATM status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 2 (3 open) [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CCNE1 +
CCNE1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK12 +
CDK12 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
DDR2 +
DDR2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
EPHA2 +
EPHA2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB4 +
ERBB4 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERCC4 +
ERCC4 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERCC5 +
ERCC5 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCE status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCF status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCG status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCI status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCL status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FANCM status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
FBXW7 +
FBXW7 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FGFR4 +
FGFR4 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FH +
FH is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 0 are open and 2 are closed. Of the trials that contain FH status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FRK +
FRK is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FRK status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains KDR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 15 clinical trials for gastrointestinal stromal tumor, of which 14 are open and 1 is closed. Of the trials that contain KIT status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 4 are phase 3 (3 open) [3].
Imatinib has evidence of efficacy in patients with KIT mutation in gastrointestinal stromal tumor [3].
KRAS +
KRAS is an inclusion eligibility criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [3].
MAPK11 +
MAPK11 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MDM4 +
MDM4 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain MRE11A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain MYC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain NBN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
NF1 +
NF1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains NF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 16 clinical trials for gastrointestinal stromal tumor, of which 14 are open and 2 are closed. Of the trials that contain PDGFRA status and gastrointestinal stromal tumor as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 5 are phase 3 (4 open) [3].
Avapritinib, dasatinib, and imatinib have evidence of efficacy in patients with PDGFRA mutation in gastrointestinal stromal tumor [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains POLE status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PPP2R1A +
PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
RET +
RET is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
SDHA +
SDHA is an inclusion eligibility criterion in 4 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 2 are closed. Of the trials that contain SDHA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
SDHAF2 +
SDHAF2 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain SDHAF2 status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
SDHB +
SDHB is an inclusion eligibility criterion in 4 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 2 are closed. Of the trials that contain SDHB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
SDHC +
SDHC is an inclusion eligibility criterion in 4 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 2 are closed. Of the trials that contain SDHC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
SDHD +
SDHD is an inclusion eligibility criterion in 4 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 2 are closed. Of the trials that contain SDHD status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
STAG2 +
STAG2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TEK +
TEK is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains TEK status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
TRNAK2 +
TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFA +
VEGFA is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFB +
VEGFB is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
VEGFC +
VEGFC is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
